Author(s): Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et al. Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et al. Abstract: P603 Session topic: 8. Chronic myeloid leukemia – Clinical Background: Ponatinib is an oral tyrosine kinase inhibitor (TKI) approved for pts with CP-CML or Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+...
Pro zobrazení tohoto obsahu je třeba být přihlášen.